Hosted by IDTechEx
HomeWebinarsEventsReportsTVCareersAbout UsIDTechExTwitterFacebookLinkedInYoutubeRSSForward To Friend
Global Biotechnology Insights
Posted on August 10, 2018

Next gen nVNS therapy available for patients with migraine in the USA

electroCore Inc, a commercial-stage bioelectronic medicine company, has announced gammaCore Sapphire™, the next generation of gammaCore (non-invasive vagus nerve stimulator or nVNS), is now available in the United States. gammaCore is the first U.S. Food and Drug Administration cleared, nVNS device for the acute treatment of pain associated with migraine and episodic cluster headache. For more information see the IDTechEx report on digital health 2018.
gammaCore Sapphire is the next generation of gammaCore nVNS therapy, which is designed as a portable, easy-to-use technology that can be self-administered by patients as needed for the pain associated with migraine and episodic cluster headache without the potential side effects associated with commonly prescribed medicines. When placed on a patient's neck over the vagus nerve, gammaCore stimulates the nerve's fibers, resulting in the reduction of pain. The improved design features of gammaCore Sapphire include:
  • A sleeker, smaller handheld device that is easy for patients to grip
  • Smoother stimulation surfaces for easy placement over the vagus nerve
  • Intensity buttons positioned on the side of the device to facilitate therapy adjustments
  • A larger, brighter display to communicate status information, even in the dark
Additionally, gammaCore Sapphire includes added functionality intended for multi-year use, with a rechargeable function and reloadable refill capability. It can be activated monthly through the input of a unique, prescription-only authorization code, delivered via a radio-frequency identification card that is mailed directly to the patient.
"gammaCore Sapphire offers more convenience to patients with an enhanced designed and added functionalities that make the therapy application more seamless and even more patient-centric than the device's previous generation," said Dan Duhart, Chief Commercial Officer of electroCore. "Constantly innovating to deliver the next-generation device is just one example of our commitment to providing relief to patients suffering from the debilitating pain of migraine and episodic cluster headache."
gammaCore is prescribed by a physician and each device allows for treatment of multiple headaches per day up to 24 stimulations per day.
Source and top image: electroCore Inc
Learn more at the next leading event on the topic: Business and Technology Insight Forum. Boston, June 2019 External Link on 4 - 6 Jun 2019 at Boston, USA hosted by IDTechEx.